Covered recipient · General Payments record
AUNG NAING
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$2,639.00
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,639.00 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $2,639.00 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AUNG NAING
NPI 1104837590 · CMS profile ID 366226
Allopathic & Osteopathic Physicians / Internal Medicine
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- AUNG NAING, NPI 1104837590, CMS profile ID 366226, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $2,639.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Incyte Corporation | $2,639.00 | 04/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835545359 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,918,481.53 | 469 |
| PY2024 | Recipient | $4,531.10 | 4 |
| PY2024 | Principal investigator | $4,445,667.71 | 159 |
| PY2023 | Principal investigator | $4,761,955.67 | 97 |
| PY2022 | Principal investigator | $3,708,621.77 | 334 |
| PY2021 | Principal investigator | $5,802,399.26 | 154 |
| PY2020 | Recipient | $2,459.66 | 4 |
| PY2020 | Principal investigator | $1,927,221.68 | 148 |
| PY2019 | Principal investigator | $5,972,979.75 | 356 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
356 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | EMD Serono, Inc. | $61.00 | 12/31/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703030559 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 12/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666473035 |
| Principal investigator 1 | EMD Serono, Inc. | $61.00 | 11/30/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703030543 |
| Principal investigator 1 | Incyte Corporation | $9,748.80 | 11/26/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459681 |
| Principal investigator 1 | Incyte Corporation | $89,053.20 | 11/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459675 |
| Principal investigator 1 | Incyte Corporation | $57,932.10 | 11/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459677 |
| Principal investigator 1 | Incyte Corporation | $61.84 | 11/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459487 |
| Principal investigator 1 | Incyte Corporation | $14.20 | 11/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459489 |
| Principal investigator 1 | Incyte Corporation | $70.32 | 11/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459491 |
| Principal investigator 1 | Incyte Corporation | $191.00 | 11/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459493 |
| Principal investigator 1 | Incyte Corporation | $6.40 | 11/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459509 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 11/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459511 |
| Principal investigator 1 | EMD Serono, Inc. | $1,621.80 | 11/04/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703034305 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 11/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666473033 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $203,484.00 | 11/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers | No dispute reported | 06/30/2026 | 691538153 |
| Principal investigator 1 | EMD Serono, Inc. | $61.00 | 10/31/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703030535 |
| Principal investigator 1 | Incyte Corporation | $14,676.77 | 10/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B Cell Malignancies | No dispute reported | 06/30/2026 | 666458805 |
| Principal investigator 1 | Incyte Corporation | $56,531.70 | 10/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $768.00 | 10/23/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 639740661 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $20,781.52 | 10/23/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 639740663 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,456.84 | 10/23/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 639740665 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $190.08 | 10/23/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 639740667 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,000.00 | 10/23/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 639740669 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,140.00 | 10/23/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 639740671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,607.76 | 10/23/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 639740673 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 10/23/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 PD 1, AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 639740675 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 10/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666458803 |
| Principal investigator 1 | Incyte Corporation | $30,842.10 | 10/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459669 |
| Principal investigator 1 | Incyte Corporation | $185.52 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459315 |
| Principal investigator 1 | Incyte Corporation | $58.50 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459431 |
| Principal investigator 1 | Incyte Corporation | $7.10 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459433 |
| Principal investigator 1 | Incyte Corporation | $1.20 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459435 |
| Principal investigator 1 | Incyte Corporation | $9.92 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459437 |
| Principal investigator 1 | Incyte Corporation | $123.68 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459439 |
| Principal investigator 1 | Incyte Corporation | $175.80 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459441 |
| Principal investigator 1 | Incyte Corporation | $329.45 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459443 |
| Principal investigator 1 | Incyte Corporation | $38.70 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459445 |
| Principal investigator 1 | Incyte Corporation | $2.56 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459447 |
| Principal investigator 1 | Incyte Corporation | $188.00 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459449 |
| Principal investigator 1 | Incyte Corporation | $76.40 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459451 |
| Principal investigator 1 | Incyte Corporation | $169.44 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459453 |
| Principal investigator 1 | Incyte Corporation | $48.48 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459455 |
| Principal investigator 1 | Incyte Corporation | $5.04 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459457 |
| Principal investigator 1 | Incyte Corporation | $14.08 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459459 |
| Principal investigator 1 | Incyte Corporation | $162.72 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459461 |
| Principal investigator 1 | Incyte Corporation | $76.40 | 10/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459499 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 10/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666473031 |
| Principal investigator 1 | EMD Serono, Inc. | $61.00 | 09/30/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703030519 |
| Principal investigator 1 | Incyte Corporation | $355,021.30 | 09/30/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 | No dispute reported | 06/30/2026 | 666459563 |
| Principal investigator 1 | Incyte Corporation | $1,113.31 | 09/30/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 | No dispute reported | 06/30/2026 | 666459565 |
| Principal investigator 1 | Incyte Corporation | $12,829.00 | 09/26/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 | No dispute reported | 06/30/2026 | 666459561 |
| Principal investigator 1 | Incyte Corporation | $20.26 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459219 |
| Principal investigator 1 | Incyte Corporation | $9.55 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459221 |
| Principal investigator 1 | Incyte Corporation | $131.78 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459223 |
| Principal investigator 1 | Incyte Corporation | $105.48 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459225 |
| Principal investigator 1 | Incyte Corporation | $565.74 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459227 |
| Principal investigator 1 | Incyte Corporation | $76.40 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459247 |
| Principal investigator 1 | Incyte Corporation | $84.72 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459249 |
| Principal investigator 1 | Incyte Corporation | $70.32 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459251 |
| Principal investigator 1 | Incyte Corporation | $188.00 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459253 |
| Principal investigator 1 | Incyte Corporation | $61.84 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459255 |
| Principal investigator 1 | Incyte Corporation | $24.24 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459257 |
| Principal investigator 1 | Incyte Corporation | $5.04 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459259 |
| Principal investigator 1 | Incyte Corporation | $7.04 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459261 |
| Principal investigator 1 | Incyte Corporation | $117.50 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459263 |
| Principal investigator 1 | Incyte Corporation | $58.50 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459265 |
| Principal investigator 1 | Incyte Corporation | $211.80 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459267 |
| Principal investigator 1 | Incyte Corporation | $45.45 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459269 |
| Principal investigator 1 | Incyte Corporation | $6.30 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459271 |
| Principal investigator 1 | Incyte Corporation | $101.70 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459273 |
| Principal investigator 1 | Incyte Corporation | $13.20 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459275 |
| Principal investigator 1 | Incyte Corporation | $76.40 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459291 |
| Principal investigator 1 | Incyte Corporation | $76.40 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459293 |
| Principal investigator 1 | Incyte Corporation | $131.78 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459295 |
| Principal investigator 1 | Incyte Corporation | $76.40 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459297 |
| Principal investigator 1 | Incyte Corporation | $117.50 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459299 |
| Principal investigator 1 | Incyte Corporation | $58.50 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459301 |
| Principal investigator 1 | Incyte Corporation | $58.50 | 09/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459303 |
| Principal investigator 1 | EMD Serono, Inc. | $3,243.60 | 09/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703035285 |
| Principal investigator 1 | EMD Serono, Inc. | $62,525.00 | 09/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | MS201408-0005 | No dispute reported | 06/30/2026 | 703037211 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 09/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472827 |
| Principal investigator 1 | EMD Serono, Inc. | $61.00 | 08/31/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703030503 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $158,664.50 | 08/26/2019 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | MEDI4736 anti-PD-L1 mab Solid Tumor-MEDI4736 Basket Study (Ph2a) | No dispute reported | 06/30/2026 | 685003967 |
| Principal investigator 1 | Incyte Corporation | $87.50 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500931 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500933 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500935 |
| Principal investigator 1 | Incyte Corporation | $87.50 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501065 |
| Principal investigator 1 | Incyte Corporation | $87.50 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501067 |
| Principal investigator 1 | Incyte Corporation | $87.50 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501069 |
| Principal investigator 1 | Incyte Corporation | $87.50 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501071 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501073 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501075 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501077 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501079 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501081 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501083 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501085 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501087 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501089 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501091 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501093 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501095 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501097 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501099 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501101 |
| Principal investigator 1 | Incyte Corporation | $8.00 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501103 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501105 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501107 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501109 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501111 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501113 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501115 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501153 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501155 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501157 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501159 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501161 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501163 |
| Principal investigator 1 | Incyte Corporation | $1,875.00 | 08/20/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459401 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 08/20/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459403 |
| Principal investigator 1 | Incyte Corporation | $169.00 | 08/20/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459405 |
| Principal investigator 1 | Incyte Corporation | $180.00 | 08/20/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459407 |
| Principal investigator 1 | Incyte Corporation | $625.00 | 08/20/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459409 |
| Principal investigator 1 | Incyte Corporation | $3,475.19 | 08/20/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459411 |
| Principal investigator 1 | Incyte Corporation | $780.00 | 08/20/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459413 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500929 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501043 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501045 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501047 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501049 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501051 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501053 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501055 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501057 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501059 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501061 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501063 |
| Principal investigator 1 | Incyte Corporation | $29,771.10 | 08/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459397 |
| Principal investigator 1 | Incyte Corporation | $39,553.20 | 08/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459399 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 08/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472825 |
| Principal investigator 1 | EMD Serono, Inc. | $61.00 | 07/31/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703030487 |
| Principal investigator 1 | Incyte Corporation | $22,253.00 | 07/30/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 | No dispute reported | 06/30/2026 | 666459393 |
| Principal investigator 1 | Incyte Corporation | $725.40 | 07/30/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459395 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $132,942.88 | 07/19/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers | No dispute reported | 06/30/2026 | 691517483 |
| Principal investigator 1 | Incyte Corporation | $2,037.05 | 07/11/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666458789 |
| Principal investigator 1 | Incyte Corporation | $1,572.62 | 07/11/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666458791 |
| Principal investigator 1 | Incyte Corporation | $4,478.05 | 07/11/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666458793 |
| Principal investigator 1 | Incyte Corporation | $64,252.70 | 07/11/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666458797 |
| Principal investigator 1 | Incyte Corporation | $47.75 | 07/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459199 |
| Principal investigator 1 | Incyte Corporation | $211.50 | 07/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459201 |
| Principal investigator 1 | Incyte Corporation | $23.40 | 07/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459203 |
| Principal investigator 1 | Incyte Corporation | $140.40 | 07/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459205 |
| Principal investigator 1 | Incyte Corporation | $105.30 | 07/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459207 |
| Principal investigator 1 | Incyte Corporation | $46.80 | 07/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459209 |
| Principal investigator 1 | Incyte Corporation | $11.34 | 07/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459211 |
| Principal investigator 1 | Incyte Corporation | $413.01 | 07/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459213 |
| Principal investigator 1 | Incyte Corporation | $54.54 | 07/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459215 |
| Principal investigator 1 | Incyte Corporation | $15.84 | 07/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459217 |
| Principal investigator 1 | Incyte Corporation | $211.50 | 07/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459285 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 07/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472823 |
| Principal investigator 1 | EMD Serono, Inc. | $69.79 | 06/30/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703031077 |
| Principal investigator 1 | Incyte Corporation | $170,414.88 | 06/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B Cell Malignancies | No dispute reported | 06/30/2026 | 666458785 |
| Principal investigator 1 | Incyte Corporation | $282,407.89 | 06/20/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666458783 |
| Principal investigator 1 | Incyte Corporation | $20.26 | 06/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459185 |
| Principal investigator 1 | Incyte Corporation | $117.00 | 06/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459187 |
| Principal investigator 1 | Incyte Corporation | $47.75 | 06/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459189 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $132,942.88 | 06/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers | No dispute reported | 06/30/2026 | 691455301 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 06/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666467495 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 06/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472821 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 06/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472841 |
| Principal investigator 1 | EMD Serono, Inc. | $1,441.60 | 05/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703034069 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 05/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703034515 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $36,874.50 | 05/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | Phase IIB TMB High Pan Tumor Monotherapy | No dispute reported | 06/30/2026 | 639761851 |
| Principal investigator 1 | Incyte Corporation | $47.75 | 05/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459181 |
| Principal investigator 1 | Incyte Corporation | $114.60 | 05/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459183 |
| Principal investigator 1 | Incyte Corporation | $47.75 | 05/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459195 |
| Principal investigator 1 | Incyte Corporation | $47.75 | 05/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459197 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500927 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501009 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501011 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501013 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501015 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501017 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501019 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501021 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501023 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501025 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501027 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501029 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501031 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501033 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501035 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501037 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501039 |
| Principal investigator 1 | Incyte Corporation | $315.00 | 05/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501041 |
| Principal investigator 1 | Incyte Corporation | $77.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500917 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500919 |
| Principal investigator 1 | Incyte Corporation | $7.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500921 |
| Principal investigator 1 | Incyte Corporation | $21.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500923 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500925 |
| Principal investigator 1 | Incyte Corporation | $77.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500977 |
| Principal investigator 1 | Incyte Corporation | $77.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500979 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500981 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500983 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500985 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500987 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500989 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500991 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500993 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500995 |
| Principal investigator 1 | Incyte Corporation | $7.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500997 |
| Principal investigator 1 | Incyte Corporation | $7.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500999 |
| Principal investigator 1 | Incyte Corporation | $21.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501001 |
| Principal investigator 1 | Incyte Corporation | $21.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501003 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501005 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 05/03/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666501007 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 05/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666467493 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 05/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472819 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 05/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472835 |
| Principal investigator 1 | Incyte Corporation | $74,719.80 | 04/30/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459381 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500877 |
| Principal investigator 1 | Incyte Corporation | $7.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500879 |
| Principal investigator 1 | Incyte Corporation | $21.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500881 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500883 |
| Principal investigator 1 | Incyte Corporation | $35.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500885 |
| Principal investigator 1 | Incyte Corporation | $77.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500887 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500889 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500891 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500893 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500895 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500897 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500899 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500901 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500903 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500905 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500907 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500909 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500911 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500913 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500915 |
| Principal investigator 1 | Incyte Corporation | $7.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500937 |
| Principal investigator 1 | Incyte Corporation | $7.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500939 |
| Principal investigator 1 | Incyte Corporation | $7.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500941 |
| Principal investigator 1 | Incyte Corporation | $7.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500943 |
| Principal investigator 1 | Incyte Corporation | $21.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500945 |
| Principal investigator 1 | Incyte Corporation | $21.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500947 |
| Principal investigator 1 | Incyte Corporation | $21.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500949 |
| Principal investigator 1 | Incyte Corporation | $21.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500951 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500953 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500955 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500957 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500959 |
| Principal investigator 1 | Incyte Corporation | $35.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500961 |
| Principal investigator 1 | Incyte Corporation | $35.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500963 |
| Principal investigator 1 | Incyte Corporation | $35.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500965 |
| Principal investigator 1 | Incyte Corporation | $35.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500967 |
| Principal investigator 1 | Incyte Corporation | $77.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500969 |
| Principal investigator 1 | Incyte Corporation | $77.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500971 |
| Principal investigator 1 | Incyte Corporation | $77.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500973 |
| Principal investigator 1 | Incyte Corporation | $77.00 | 04/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | No dispute reported | 06/30/2026 | 666500975 |
| Principal investigator 1 | Incyte Corporation | $70.32 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459153 |
| Principal investigator 1 | Incyte Corporation | $65.89 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459155 |
| Principal investigator 1 | Incyte Corporation | $377.16 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459157 |
| Principal investigator 1 | Incyte Corporation | $754.32 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459159 |
| Principal investigator 1 | Incyte Corporation | $46.80 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459161 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459163 |
| Principal investigator 1 | Incyte Corporation | $60.80 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459165 |
| Principal investigator 1 | Incyte Corporation | $12.32 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459167 |
| Principal investigator 1 | Incyte Corporation | $70.50 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459169 |
| Principal investigator 1 | Incyte Corporation | $38.20 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459171 |
| Principal investigator 1 | Incyte Corporation | $6.12 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459173 |
| Principal investigator 1 | Incyte Corporation | $131.78 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459175 |
| Principal investigator 1 | Incyte Corporation | $40.88 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459177 |
| Principal investigator 1 | Incyte Corporation | $183.06 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459179 |
| Principal investigator 1 | Incyte Corporation | $70.32 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459191 |
| Principal investigator 1 | Incyte Corporation | $70.50 | 04/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666459193 |
| Principal investigator 1 | Incyte Corporation | $22,790.75 | 04/05/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B Cell Malignancies | No dispute reported | 06/30/2026 | 666458705 |
| Principal investigator 1 | EMD Serono, Inc. | $15,773.00 | 04/04/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703036815 |
| Principal investigator 1 | EMD Serono, Inc. | $46,419.68 | 04/04/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703037157 |
| Principal investigator 1 | Incyte Corporation | $4,094.45 | 04/04/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666458699 |
| Principal investigator 1 | Incyte Corporation | $3,453.55 | 04/04/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666458701 |
| Principal investigator 1 | Incyte Corporation | $333,178.20 | 04/02/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459375 |
| Principal investigator 1 | Incyte Corporation | $52,391.70 | 04/02/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459377 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 04/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666467491 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 04/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472817 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 04/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472829 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $203,653.50 | 03/29/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients with Advanced Types of Cancers | No dispute reported | 06/30/2026 | 691536825 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,052.55 | 03/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | Phase IIB TMB High Pan Tumor Monotherapy | No dispute reported | 06/30/2026 | 639761853 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,995.72 | 03/20/2019 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | MEDI1873 GITRL Solid Tmr-D6150C00001 Phase 1 Clinical Trial | No dispute reported | 06/30/2026 | 685003929 |
| Principal investigator 1 | Incyte Corporation | $1,994.10 | 03/14/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666458679 |
| Principal investigator 1 | Incyte Corporation | $19,273.50 | 03/12/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459359 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 03/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459075 |
| Principal investigator 1 | Incyte Corporation | $263.56 | 03/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459117 |
| Principal investigator 1 | Incyte Corporation | $754.32 | 03/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459119 |
| Principal investigator 1 | Incyte Corporation | $117.50 | 03/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459123 |
| Principal investigator 1 | Incyte Corporation | $76.40 | 03/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459129 |
| Principal investigator 1 | Incyte Corporation | $105.90 | 03/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459131 |
| Principal investigator 1 | Incyte Corporation | $30.30 | 03/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459133 |
| Principal investigator 1 | Incyte Corporation | $8.80 | 03/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459135 |
| Principal investigator 1 | Incyte Corporation | $101.70 | 03/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459137 |
| Principal investigator 1 | Incyte Corporation | $3.15 | 03/08/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459139 |
| Principal investigator 1 | EMD Serono, Inc. | $1,621.80 | 03/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703034303 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 03/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666467499 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 03/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472637 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 03/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472653 |
| Principal investigator 1 | EMD Serono, Inc. | $113.39 | 02/28/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | MS2014080005 | No dispute reported | 06/30/2026 | 703031729 |
| Principal investigator 1 | EMD Serono, Inc. | $113.39 | 02/28/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | MS2014080005 | No dispute reported | 06/30/2026 | 703031731 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $67,884.50 | 02/26/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients with Advanced Types of Cancers | No dispute reported | 06/30/2026 | 691296327 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $326.63 | 02/25/2019 | Non-covered Recipient Entity University Of Texas Md Anderson Cancer Center | Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway | No dispute reported | 06/30/2026 | 639761849 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,991.25 | 02/25/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE IB II OPEN LABEL MULTICENTER STUDY OF MCS110 IN COMBINATION WITH PDR001 IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 640706613 |
| Principal investigator 1 | EMD Serono, Inc. | $3,594.00 | 02/20/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | MS 201408-0005 | No dispute reported | 06/30/2026 | 703035433 |
| Principal investigator 1 | Incyte Corporation | $20,500.00 | 02/14/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459349 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 02/14/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459351 |
| Principal investigator 1 | Incyte Corporation | $7,000.00 | 02/14/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459353 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 02/14/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459355 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 02/14/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459357 |
| Principal investigator 1 | Eli Lilly and Company | $2,240,853.08 | 02/11/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 STUDY OF PEGILODECAKIN (LY3500518) IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 654287885 |
| Principal investigator 1 | Incyte Corporation | $650.00 | 02/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer | No dispute reported | 06/30/2026 | 666459341 |
| Principal investigator 1 | Incyte Corporation | $848.00 | 02/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer | No dispute reported | 06/30/2026 | 666459343 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 02/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer | No dispute reported | 06/30/2026 | 666459345 |
| Principal investigator 1 | Incyte Corporation | $250.00 | 02/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer | No dispute reported | 06/30/2026 | 666459347 |
| Principal investigator 1 | Incyte Corporation | $121,872.75 | 02/06/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B Cell Malignancies | No dispute reported | 06/30/2026 | 666458697 |
| Principal investigator 1 | Incyte Corporation | $23,255.10 | 02/05/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459339 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 02/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666467497 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 02/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472635 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 02/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472647 |
| Principal investigator 1 | EMD Serono, Inc. | $113.39 | 01/31/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | MS2014080005 | No dispute reported | 06/30/2026 | 703031733 |
| Principal investigator 1 | EMD Serono, Inc. | $113.39 | 01/31/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | MS2014080005 | No dispute reported | 06/30/2026 | 703031735 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $299,458.95 | 01/31/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE I AND OR II OPEN LABEL MULTI CENTER STUDY OF THE SAFETY AND EFFICACY OF BLZ945 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULTS PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 640708665 |
| Principal investigator 1 | Incyte Corporation | $93.60 | 01/28/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459065 |
| Principal investigator 1 | Incyte Corporation | $162.72 | 01/28/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459067 |
| Principal investigator 1 | Incyte Corporation | $169.44 | 01/28/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459069 |
| Principal investigator 1 | Incyte Corporation | $93.60 | 01/28/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459079 |
| Principal investigator 1 | EMD Serono, Inc. | $1,621.80 | 01/22/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | EMR 200647-001 | No dispute reported | 06/30/2026 | 703034301 |
| Principal investigator 1 | EMD Serono, Inc. | $31,250.00 | 01/21/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | MS 201408-0005 | No dispute reported | 06/30/2026 | 703037079 |
| Principal investigator 1 | EMD Serono, Inc. | $9,419.00 | 01/18/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | MS 201408-0005 | No dispute reported | 06/30/2026 | 703036427 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 01/17/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666458691 |
| Principal investigator 1 | Incyte Corporation | $350.00 | 01/17/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666458693 |
| Principal investigator 1 | Incyte Corporation | $2,579.00 | 01/17/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 | No dispute reported | 06/30/2026 | 666459335 |
| Principal investigator 1 | Incyte Corporation | $19,733.00 | 01/17/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 | No dispute reported | 06/30/2026 | 666459337 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $22,346.10 | 01/16/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies CheckMate 627 | No dispute reported | 06/30/2026 | 639761847 |
| Principal investigator 1 | Incyte Corporation | $22,566.60 | 01/15/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459325 |
| Principal investigator 1 | Incyte Corporation | $7,000.00 | 01/15/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer | No dispute reported | 06/30/2026 | 666459327 |
| Principal investigator 1 | Incyte Corporation | $21,250.00 | 01/15/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer | No dispute reported | 06/30/2026 | 666459329 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 01/15/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer | No dispute reported | 06/30/2026 | 666459331 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 01/15/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer | No dispute reported | 06/30/2026 | 666459333 |
| Principal investigator 1 | Incyte Corporation | $48,853.80 | 01/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459321 |
| Principal investigator 1 | Incyte Corporation | $20,447.10 | 01/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666459323 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $84,282.38 | 01/10/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | OPEN LABEL MULTICENTER PHASE L AND OR LL STUDY OF THE SAFETY AND EFFICACY OF PDR001 ADMINISTERED TO PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 640708661 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $46,756.00 | 01/07/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE I THROUGH IB AND OR II OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 640706609 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 01/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472629 |
| Principal investigator 1 | Incyte Corporation | $16.00 | 01/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472631 |
| Principal investigator 1 | Incyte Corporation | $38.00 | 01/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472633 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 01/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open Label, Multicenter, Nonrandomized, Dose Escalation, and Tumor Expansion Phase 12 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat INCB024360, With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 666472639 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 01/01/2019 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Phase 12 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 666472641 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $140.00 | 01/01/2019 | Non-covered Recipient Entity UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | A PHASE I AND OR II MULTICENTER OPEN LABEL STUDY OF ORAL FGF401 IN ADULT PATIENTS WITH HEPATOCELLULAR CARCINOMA OR SOLID MALIGNANCIES CHARACTERIZED BY POSITIVE FGFR4 AND KLB EXPRESSION | No dispute reported | 06/30/2026 | 640729987 |